Skip to content

    Fredun Pharma

    539730
    Healthcare·11 Nov 2025
    Management Summary

    Fredun Pharmaceuticals Limited reported a strong Q2 and H1 FY26, with significant year-on-year growth in revenue, EBITDA, and net profit. The company reinforced its focus on high-margin businesses and expanded its footprint in the pet care segment through strategic acquisitions of One Pet Stop Private Limited and Wagr.ai. Product innovation was highlighted with the launch of Snacky Jain, and manufacturing capacity expansion is underway to support growing demand.

    Highlights

    8
    • Q2 FY26 Total income stood at INR 145.29 crores, growing by 35% year-on-year.

    • Q2 FY26 EBITDA grew by 60% to INR 22.34 crores, with margin improving to 15.37%.

    • Q2 FY26 Net profit grew by 128% to INR 9.73 crores.

    • H1 FY26 Total income stood at INR 265.15 crores, grew by 42%.

    • H1 FY26 EBITDA grew by 61% to INR 39.33 crores, and PAT grew by 96% to INR 16.50 crores.

    • Acquired One Pet Stop Private Limited and Wagr.ai to strengthen pet care offerings.

    • Launched Snacky Jain, India's first pure Jain functional food for pets, with 12 tons already sold through preorders.

    • Commenced expansion of state-of-the-art manufacturing facility at Palghar to enhance capacity.

    What Changed1

    vs Q3 FY26

    Guidance items9 → 5 (-4)
    Key financials

    Metrics

    7

    Periods

    2

    Q2 FY26

    4
    • Total Income
      ₹145.29 Cr
      YoY+35%
    • EBITDA
      ₹22.34 Cr
      YoY+60%
    • EBITDA Margin
      15.4%
    • Net Profit
      ₹9.73 Cr
      YoY+128%

    H1 FY26

    3
    • Total Income
      ₹265.15 Cr
      YoY+42%
    • EBITDA
      ₹39.33 Cr
      YoY+61%
    • PAT
      ₹16.5 Cr
      YoY+96%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    M&A

    One Pet Stop Private Limited

    acquisition · closed

    M&A

    Wagr.ai

    acquisition · closed · Consideration ₹0 crores (stock)

    M&A

    Wagr.ai Platform Development

    Other · announced · Consideration ₹4 crores (cash)

    Guidance & targets

    5
    CategoryTargetPriority
    Business Mix
    US Business Contribution to Revenue
    over 51%
    High
    Market Share
    Pet Wellness Ecosystem Dominance
    no pet in India should be born or die without using Freossi products
    High
    Revenue Growth
    Vintage Business CAGR
    around 15%
    High
    Revenue Growth
    Mobility Segment YoY Growth
    25% to 30%
    High
    Net Profit
    PAT
    INR 90 crores
    High

    Palghar Manufacturing Facility Expansion Progress

    Next quarter / within 2 years
    CurrentCommenced expansion, aiming to be one of the largest plants in the country within 2 years.
    TargetContinued progress on expansion, specific milestones or capacity additions.

    Why it matters

    Essential for enhancing capacity, improving operational efficiency, and meeting growing demand across domestic and international markets.

    We have commenced expansion of our state-of-the-art manufacturing facility at Palghar to enhance capacity, improve operational efficiency, and support the growing demand across both domestic and international markets.

    How to verify

    detailed_narrative

    0

    Q&A highlights

    8

    “So, in a cluster of 3 plants, we can make a huge number of products. However, considering the product portfolio that we need to add for our future, we have added 37 locations across India in the last 24 months, where we ourselves will manufacture products, which we cannot manufacture in our own facilities due to licensing constraints, due to other MOQs and stuff like that. Considering that right now, the outsourced products are hardly about 5% to 7%. And this will increase to about 15% to 20% in the coming years as we ourselves are also increasing the capacity of our manufacturing as I'm sure you must have heard that we have started an expansion. So hopefully, within the next 2 years, we should be one of the largest plants for a single location in the country.”

    Clarifies the company's manufacturing strategy, capacity expansion plans, and how outsourcing contributes to cost efficiency and margin improvement.

    asked by Pal Balar

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Q2 & H1 FY26 Financial Performance

    Fredun Pharmaceuticals Limited delivered robust financial results for Q2 FY26, with total income reaching INR 145.29 crores, marking a 35% year-on-year increase. EBITDA surged by 60% to INR 22.34 crores, improving the margin to 15.37%, while net profit saw a significant 128% jump to INR 9.73 crores. For the first half of FY26, total income grew 42% to INR 265.15 crores, EBITDA increased 61% to INR 39.33 crores, and PAT rose 96% to INR 16.50 crores, demonstrating healthy momentum across new age verticals.

    02

    Strategic Expansion in Pet Care Segment

    The company significantly expanded its presence in the fast-growing pet care segment through two strategic acquisitions. One Pet Stop Private Limited, a tech-enabled pet grooming and wellness platform, was acquired to integrate products and services and reach a broader consumer base. Additionally, Wagr.ai, a pioneering pet tech platform offering GPS tracking and veterinary consultation, was acquired at zero cost, with plans to invest INR 4-5 crores in the next 18-24 months for platform development. This strategy aims to build a connected technology-led pet wellness ecosystem under the Freossi brand.

    03

    Product Innovation and Market Traction

    Fredun Pharma launched Snacky Jain, India's first pure Jain functional food for pets, developed through in-house R&D. This 100% vegetarian snack, enriched with calcium and essential nutrients, has already seen 12 tons sold through preorders and is rolling out across 6 major cities. The company also highlighted innovative products in cosmeceuticals, such as an SPF 100 sunscreen in a single-use sachet and cost-effective wet wipes, which have gained significant market traction.

    04

    Manufacturing Capacity Enhancement

    To support growing demand and improve operational efficiency, Fredun Pharmaceuticals has commenced the expansion of its state-of-the-art manufacturing facility in Palghar. The company aims for this facility to become one of the largest single-location plants in the country within the next two years. This expansion is crucial for enhancing capacity across its diverse product portfolio, including branded generics, nutraceuticals, cosmeceuticals, animal healthcare, and mobility aids.

    05

    Diversified Business Segment Growth Strategy

    While pet care is a key focus, Fredun Pharma maintains a diversified approach, with 1,600 other products in allopathic and GX ranges performing well. The mobility segment is anticipated to grow 25-30% year-on-year, leveraging existing distribution channels. Nutraceuticals are supported by double-blinded clinical trials and offer complementary products to allopathic formulations. The company's long-term vision includes 51% of revenue from the U.S. business by FY32 and aims for its vintage business to grow at a 15% CAGR over the next 7-9 years.

    06

    Capital Allocation for Strategic Growth

    The company's recently raised funds are being strategically allocated to new product development, team building, marketing, distribution, capex, and reserves. This growth capital is intended to expedite the company's journey towards its 2029-2030 goals, particularly in new-age businesses. A significant portion will also be directed towards working capital to support the launch of new SKUs, ensuring sustainable growth and improved margins in the long run.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.